SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare informs about clarification

28 Dec 2016 Evaluate

Cadila Healthcare has informed that with reference to news appearing in the media this morning, they wish to clarify that this matter very specifically relates to an Untitled Letter issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare) and not a Warning Letter. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed only in India. We have already taken the necessary actions to respond to this letter. As per the USFDA website, ‘Unlike a warning letter, an Untitled Letter does not include a statement warning that failure to promptly correct a violation may result in an enforcement action’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×